Analystreport

Revance Therapeutics Inc (NASDAQ: RVNC) was given a new $40.00 price target on by analysts at Barclays PLC. They now have a "buy" rating on the stock.

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com